Recombinant Human GALNT7 Protein, CF
Recombinant Human GALNT7 Protein, CF Summary
Product Specifications
Leu28-Val657, with a C-terminal 6-His tag
Analysis
Product Datasheets
7748-GT
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
7748-GT
| Formulation | Supplied as a 0.2 μm filtered solution in Tris and NaCl. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Assay Procedure
- Assay Buffer: 25 mM Tris, 5 mM MnCl2 (supplied in kit), 2.5 mM CaCl2, pH 7.5
- Recombinant Human Polypeptide GalNac Transferase 7/GALNT7 (rhGALNT7) (Catalog # 7748-GT)
- UDP-GalNAc (Sigma, Catalog # U5252), 10 mM stock in deionized water
- MUC5AC-3/13 Peptide (AnaSpec Inc, Catalog # 61332), 2 mM in deionized water
- Glycosyltransferase Activity Kit (Catalog # EA001)
- 96-well Clear Plate (Costar, Catalog # 92592)
- Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent
- Dilute 1 mM Phosphate Standard provided by the Glycosyltransferase Kit by adding 40 µL of the 1 mM Phosphate Standard to 360 µL of Assay Buffer for a 100 µM stock.
- Prepare standard curve by performing six one-half serial dilutions of the 100 µM Phosphate stock in Assay Buffer. The standard curve has a range of 0.078 to 5 nmol per well.
- Prepare a reaction mixture composed of 1 mM UDP-GalNAc, 0.4 mM MUC5AC-3/13 Peptide, and 8 ng/µL Coupling Phosphatase I in Assay Buffer.
- Dilute rhGALNT7 to 4 ng/µL in Assay Buffer.
- Load 50 µL of each dilution of the standard curve into a plate. Include a curve blank containing 50 μL of Assay Buffer.
- Load 25 µL of the 4 ng/µL rhGALNT7 into the plate. Include a Control containing 25 µL of Assay Buffer.
- Add 25 µL of reaction mixture to the wells, excluding the standard curve and curve blank.
- Cover the plate with parafilm or a plate sealer and incubate at 37 °C for 20 minutes.
- Add 30 µL of the Malachite Green Reagent A to all wells. Mix briefly.
- Add 100 µL of deionized water to all wells. Mix briefly.
- Add 30 µL of the Malachite Green Reagent B to all wells. Mix and incubate for 20 minutes at room temperature.
- Read plate at 620 nm (absorbance) in endpoint mode.
- Calculate specific activity:
|
Specific Activity (pmol/min/µg) = |
Phosphate released* (nmol) x (1000 pmol/nmol) |
| Incubation time (min) x amount of enzyme (µg) |
*Derived from the phosphate standard curve using linear or 4-parameter fitting and adjusted for Control.
Per Reaction:- rhGALNT7: 0.1 µg
- Coupling Phosphatase I: 0.2 µg
- MUC5AC-3/13 Peptide: 0.2 mM
- UDP-GalNAc: 0.5 mM
Background: Polypeptide GalNAc Transferase 7/GALNT7
O-glycosylation is a ubiquitous post-translational modification present in secreted and membrane-bound proteins. Polypeptide N-acetylgalactosaminyltransferases (GALNTs) catalyze the initial step for O-glycosylation by transferring GalNAc to Thr or Ser residues (GalNAc alpha 1-O-Ser/Thr) in the Golgi compartment. Structurally, the GALNTs consist of an N-terminal catalytic domain tethered by a short linker to a C-terminal ricin-like lectin domain containing three potential carbohydrate-binding sites (1, 2). Twenty distinct GALNT isoforms have been detected in humans. These isoforms display both unique and overlapping substrate specificities (3, 4, 5) with no known universal consensus glycosylation sequence. Glycosylation of mucins results from the successive, often hierarchical, action of several specific GALNTs (6). GALNT7 has a restricted preference for glycopeptides, i.e. requiring substrates that have been already decorated with GalNAc by other GALNTs, and has little redundant activity from the other family members (7, 8). Human GALNT7 is expressed in uterus, retina, kidney, small intestine, stomach and central nervous system (8). Recently, GALNT7 was identified as an oncogenic target in cervical cancer (9). The enzymatic activity of recombinant human GALNT7 was determined using a phosphatase-coupled assay (10).
- Gerken, T.A. et al. (2011) J. Biol. Chem. 286:14493.
- Ten Hagen, K.G. et al. (2003) Glycobiology 13:1R.
- Hagen, F.K. et al. (1997) J. Biol. Chem. 272:13843.
- Gerken, T.A. et al. (2006) J. Biol. Chem. 281:32403.
- Wandall, H.H. et al. (1997) J. Biol. Chem. 272:23503.
- Pratt, M.R. et al. (2004) Chem. Biol. 11:1009.
- Bennett, E. P. et al. (1999) FEBS Lett. 460:226.
- Perrine, C.L. et al. (2009) J. Biol. Chem. 284:20387.
- Peng, R.Q. et al. (2012) J. Biol. Chem. 287:14301.
- Wu, Z.L. et al. (2011) Glycobiology 21:727.
Product Specific Notices
Coomassie is a registered trademark of Imperial Chemical Industries Ltd.FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human GALNT7 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human GALNT7 Protein, CF and earn rewards!
Have you used Recombinant Human GALNT7 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
